RESUMO
Targeted protein degradation is an important mechanism carried out by the cellular machinery, one that is gaining momentum as an exploitable strategy for the development of drug-like compounds. Molecules which are able to induce proximity between elusive therapeutic targets of interest and E3 ligases which subsequently leads to proteasomal degradation of the target are beginning to decrease the percentage of the human proteome described as undruggable. Therefore, having the ability to screen for, and understand the mechanism of, such molecules is becoming an increasingly attractive scientific focus. We have established a number of cascade experiments including cell-based assays and orthogonal triage steps to provide annotation to the selectivity and mechanism of action for compounds identified as putative degraders from a primary high throughput screen against a high value oncology target. We will describe our current position, using PROTACs as proof-of-concept, on the analysis of these novel outputs and highlight challenges encountered.
Assuntos
Descoberta de Drogas , Ensaios de Triagem em Larga Escala , Proteólise , Bibliotecas de Moléculas Pequenas , Ensaios de Triagem em Larga Escala/métodos , Humanos , Descoberta de Drogas/métodos , Bibliotecas de Moléculas Pequenas/farmacologia , Proteólise/efeitos dos fármacos , Ubiquitina-Proteína Ligases/metabolismo , Complexo de Endopeptidases do Proteassoma/metabolismoRESUMO
Targeted protein degradation (TPD) is a recent strategy, utilizing the cell's proteostasis machinery to deplete specific proteins. This represents a paradigm shift in early drug discovery, away from occupancy-driven to event-driven mechanisms.Recent efforts have focused on the development of proteolysis-targeting chimeras (PROTACs). These heterobifunctional molecules combine a target-specific binding moiety linked to an E3 ligase ligand and trigger selective ubiquitination of the target protein, marking it for proteasomal degradation. While these molecules can be highly efficacious, they generally have unfavorable physicochemical properties due to their large size.In contrast, smaller molecules that induce degradation could represent an attractive, simple option to overcoming the limitations of both traditional modulators and PROTACs. These molecules may have a range of mechanisms: recruitment of an E3 ligase (molecular glues), introduction of hydrophobic areas, or inducing local unfolding, each of which triggers degradation.We recently completed a high-throughput screen of 111,000 compounds in a cellular HiBiT assay in an effort to identify such molecules. Preliminary analysis indicates that we have been able to identify alternative small-molecule degraders. We highlight methods for triage, characterization, selectivity, and mode of action. In summary, we believe that these types of small-molecule degraders, which may possibly have more acceptable physicochemical properties than the inherently larger heterobifunctional molecules, are an exciting approach for inducing TPD, and we illustrate that a general screening approach can be successful in identifying useful start points for developing such molecules.
Assuntos
Ensaios de Triagem em Larga Escala , Terapia de Alvo Molecular/métodos , Complexo de Endopeptidases do Proteassoma/metabolismo , Processamento de Proteína Pós-Traducional , Bibliotecas de Moléculas Pequenas/farmacologia , Ubiquitina-Proteína Ligases/metabolismo , Descoberta de Drogas/métodos , Células Eucarióticas/citologia , Células Eucarióticas/efeitos dos fármacos , Células Eucarióticas/metabolismo , Humanos , Interações Hidrofóbicas e Hidrofílicas , Ligantes , Ligação Proteica , Desdobramento de Proteína , Proteólise/efeitos dos fármacos , Proteômica/métodos , Proteostase/genética , Bibliotecas de Moléculas Pequenas/química , Ubiquitina-Proteína Ligases/genética , Ubiquitinação/efeitos dos fármacosRESUMO
Mitotic motor proteins of the kinesin superfamily are critical for the faithful segregation of chromosomes and the formation of the two daughter cells during meiotic and mitotic M-phase. Of the 45 human kinesins, roughly a dozen are involved in the assembly of the bipolar spindle, alignment of chromosomes at the spindle equator, chromosome segregation, and cytokinesis. The functions of kinesins in these processes are highly diverse and include the transport of cargo molecules, sliding and bundling of microtubules, and regulation of microtubule dynamics. In light of this multitude of diverse functions and the complex functional interplay of different kinesins during M-phase, it is not surprising that one of the greatest challenges in cell biology is the functional dissection of individual motor proteins. Reversible and fast acting small molecules are powerful tools to accomplish this challenge. However, the validity of conclusions drawn from small molecule studies strictly depends on compound specificity. In this chapter, we present methods for the identification of small molecule inhibitors of a motor protein of interest. In particular, we focus on a protein-based large throughput screen to identify inhibitors of the ATPase activity of kinesins. Furthermore, we provide protocols and guidelines for secondary screens to validate hits and select for specific inhibitors.
Assuntos
Bioensaio , Cinesinas/metabolismo , Mitose , Adenosina Trifosfatases/metabolismo , Animais , Automação Laboratorial , Bioensaio/instrumentação , Bioensaio/métodos , Ensaios de Triagem em Larga Escala , Humanos , Cinesinas/genética , Microtúbulos/metabolismo , Mitose/genética , Família Multigênica , Corantes de Rosanilina , SuínosRESUMO
The genetic integrity of each organism depends on the faithful segregation of its genome during mitosis. To meet this challenge, a cellular surveillance mechanism, termed the spindle assembly checkpoint (SAC), evolved that monitors the correct attachment of chromosomes and blocks progression through mitosis if corrections are needed. While the central role of the SAC for genome integrity is well established, its functional dissection has been hampered by the limited availability of appropriate small molecule inhibitors. Using a fluorescence polarization-based screen, we identify Mad2 inhibitor-1 (M2I-1), the first small molecule inhibitor targeting the binding of Mad2 to Cdc20, an essential protein-protein interaction (PPI) within the SAC. Based on computational and biochemical analyses, we propose that M2I-1 disturbs conformational dynamics of Mad2 critical for complex formation with Cdc20. Cellular studies revealed that M2I-1 weakens the SAC response, indicating that the compound might be active in cells. Thus, our study identifies the SAC specific complex formation between Mad2 and Cdc20 as a protein-protein interaction that can be targeted by small molecules.
Assuntos
Proteínas Cdc20/metabolismo , Pontos de Checagem da Fase M do Ciclo Celular/efeitos dos fármacos , Proteínas Mad2/antagonistas & inibidores , Proteínas Mad2/metabolismo , Mapas de Interação de Proteínas/efeitos dos fármacos , Bibliotecas de Moléculas Pequenas/química , Bibliotecas de Moléculas Pequenas/farmacologia , Proteínas Cdc20/antagonistas & inibidores , Células HeLa , Humanos , Mitose/efeitos dos fármacos , Simulação de Acoplamento Molecular , Fuso Acromático/efeitos dos fármacos , Fuso Acromático/metabolismoRESUMO
Cyclin J is a cyclin family member that appears to have evolved before the metazoan radiation. Its evolutionary conservation argues for an important role but functional characterizations of Cyclin J have remained very limited. In Drosophila, Cyclin J is expressed only in females. Using transgenic Drosophila lines expressing Cyclin J versions with N- or C-terminal GFP extensions, we demonstrate that it is expressed exclusively in the germline. After low level expression in all nuclei within the germarium, it gets highly enriched in the germinal vesicle within the oocyte until stage 12 of oogenesis, followed by disappearance after germinal vesicle breakdown before the first meiotic division. Surprisingly, Cyclin J is not required for female fertility. Chromosome segregation during female meiosis, as well as the rapid early embryonic cell cycles after fertilization, occurs normally in the complete absence of Cyclin J. Cyclin J with EGFP fused at either N- or C-terminus binds to Cdk1 and not to Cdk2. However, in contrast to the other known Cdk1 partners, the A- and B-type cyclins, Cyclin J is not degraded during mitosis.